INSULET CORPORATION

(PODD)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
266.60 USD   -0.75%
08/10TRANSCRIPT : Insulet Corporation Presents at Canaccord Genuity 42nd Annual Growth Conference, Aug-10-2022 04:30 PM
CI
08/08Morgan Stanley Increases Insulet's Price Target to $273 From $244, Reiterates Equalweight Rating
MT
08/05Canaccord Genuity Raises Price Target on Insulet to $290 From $250, Maintains Buy Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/11/2022 08/12/2022 08/15/2022 08/16/2022 08/17/2022 Date
264.08(c) 270.7(c) 270.64(c) 268.61(c) 266.6 Last
385 299 276 245 285 612 329 649 224 092 Volume
+0.61% +2.51% -0.02% -0.75% -0.75% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 237 M - -
Net income 2022 28,7 M - -
Net Debt 2022 637 M - -
P/E ratio 2022 666x
Yield 2022 -
Sales 2023 1 497 M - -
Net income 2023 98,7 M - -
Net Debt 2023 462 M - -
P/E ratio 2023 190x
Yield 2023 -
Capitalization 18 503 M 18 503 M -
EV / Sales 2022 15,5x
EV / Sales 2023 12,7x
Nbr of Employees 2 300
Free-Float 99,5%
More Financials
Company
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small,... 
Sector
Medical Equipment, Supplies & Distribution
Calendar
09/09 | 08:00amPresentation
More about the company
Ratings of Insulet Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about INSULET CORPORATION
08/10TRANSCRIPT : Insulet Corporation Presents at Canaccord Genuity 42nd Annual Growth Conferen..
CI
08/08Morgan Stanley Increases Insulet's Price Target to $273 From $244, Reiterates Equalweig..
MT
08/05Canaccord Genuity Raises Price Target on Insulet to $290 From $250, Maintains Buy Ratin..
MT
08/05Baird Increases Price Target on Insulet to $300 From $245, Reiterates Outperform Rating
MT
08/05Raymond James Raises Insulet's Price Target to $280 From $262, Maintains Outperform Rat..
MT
08/05Piper Sandler Adjusts Insulet's Price Target to $235 From $230, Maintains Neutral Ratin..
MT
08/05INSULET CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
08/05Insulet to Present at Upcoming Investor Conferences
BU
08/04INSULET : Q2 Earnings Snapshot
AQ
08/04TRANSCRIPT : Insulet Corporation, Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Insulet Q2 Loss Widens, Revenue Rises; Increases FY2022 Revenue Growth Guidance
MT
08/04Earnings Flash (PODD) INSULET CORPORATION Reports Q2 Revenue $285.8M
MT
08/04INSULET : Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant..
PU
08/04Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constan..
BU
08/04Insulet Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
More news
News in other languages on INSULET CORPORATION
08/04La perte d'Insulet se creuse au 2e trimestre, le chiffre d'affaires augmente, et les pr..
08/04Earnings Flash (PODD) INSULET CORPORATION annonce un chiffre d'affaires de 285,8 millio..
08/04Insulet Corporation annonce ses résultats pour le deuxième trimestre et le semestre clo..
08/04Insulet Corporation fournit des prévisions de revenus pour le trimestre se terminant le..
08/01Insulet Corporation annonce la commercialisation complète du système d'injection d'insu..
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 266,60 $
Average target price 276,40 $
Spread / Average Target 3,68%
EPS Revisions
Managers and Directors
James R. Hollingshead President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION0.20%18 643
ABBOTT LABORATORIES-20.40%196 189
MEDTRONIC PLC-7.87%126 639
BECTON, DICKINSON AND COMPANY8.96%76 370
HOYA CORPORATION-12.97%39 454
SARTORIUS STEDIM BIOTECH-18.97%36 666